The effect of virolex and immunoglobulin therapy on the specific antiviral neonatal immunity with herpes-virus infection

Abstract

Objective: the outcomes of researches conducted in Center by the employees of the department of neonatal pathology and the lab of clinical immunology have shown that the herpes-virus infection in the neonates develops on a background of immunodeficiency. The severity of infection clinical manifestations correlated with a decrease of specific antiviral antibodies level and the deficit of cells, inherings to T-helper subpopulation. The aim of the given research was the analysis of the specific humoral immunity condition in the neonates with a herpes-virus infection on a background of therapy.

Full Text

Method: 52 neonates with herpes infection affirmed with the help of methods of DNA-hybridization and ELISA were inspected. The levels of specific anti-virus IgM and IgG antibodies were determined by ELISA. The Student method for the statistical analysis was used. The specific anti-virus drug virolex and intravenous immunoglobulin containing a plenty of antibodies of different specificity including anti-herpes simplex virus (HSV) and cytomegalovirus (CMV) for the treatment of children were applied. In cases of the complicated herpes-virus infection an immunoglobulin of 4-th generation - pentaglobin was applied.

Results: the outcome of the disease for children treated by combined immunochemotherapy was favourable. The application of an immunoglobulin was accompanied by the increase of a level of the specific IgG antibodies with 1,15±0,08 up to 1,36±0,07 points (p < 0,05). The tendency to normalization of the cell immunity is marked.

Conclusion: it was shown that pentaglobin containing in a high titre of anti-HSV and anti-CMV antibodies is the most preferential at usage in the complex therapy of herpes-virus infection for the neonates.